$TSEM

Tue: Chip cos fall sharply on flat TASE

The Tel Aviv Stock Exchange was mostly flat, with the Tel Aviv 35 Index up 0.04%. Chip companies led declines, with Tower Semiconductor (TSEM) down 8.71%, Camtek (CAMT) down 5.63%, and Nova (NVMI) down 5.46%. Banks and Shufersal (SAE) rose, with Bank Hapoalim (POLI) up 1.85% and Shufersal up 4.58%.

Original reporting
Published Aug 18, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 7:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tue: Chip cos fall sharply on flat TASE — source image
Decision brief

The 30-second read

$TSEMBearishLow
01

Why it matters

The only actionable signal is the magnitude of same-day declines in TASE-listed chip/tech names (TSEM, CAMT, NVMI) alongside a 1.6% Tech Index drop.

02

Market read

Traders can use the reported dispersion to manage short-term exposure to TASE chip/tech names, but there is no new fundamental catalyst disclosed.

03

What to watch

The article lacks catalysts for the chip names; without news, traders may be over-attributing the move to fundamentals.

Relevance 4/10Novelty 2/10Timing: intraday session wrap, evening of 2026-08-18

Background

This is a daily TASE market wrap noting index performance, FX levels, and which sectors and stocks led gains and losses.

Company-level read

Ticker impact

$TSEMBearishMedium confidence
Context

Tower Semiconductor fell 8.71% as the Tech Index dropped, making it the largest decliner on the Tel Aviv 35 Index today.

Expected impact

Bearish bias for near-term trading momentum; watch for follow-through or mean reversion after the outsized move.

Evidence & confidence

The article provides a large intraday percentage decline and identifies it as the biggest fall, but gives no catalyst beyond sector weakness.

$CAMTBearishMedium confidence
Context

Camtek dropped 5.63% alongside the chip-led weakness in the Tech Index.

Expected impact

Lower near-term risk appetite for CAMT until sector tone stabilizes.

Evidence & confidence

The text reports the magnitude of the decline but does not cite company-specific news.

$NVMIBearishMedium confidence
Context

Nova Ltd. fell 5.46% as chip companies led the Tech Index lower.

Expected impact

Tactical bearish bias while the chip complex remains under pressure.

Evidence & confidence

The article reports the percentage drop and sector context, but no distinct NVMI catalyst.

$ENLTNeutralLow confidence
Context

Enlight Renewable Energy rose 0.97% during a session where the Tech Index fell 1.6% led by chip companies.

Expected impact

Mildly supportive for ENLT relative performance, but not a standalone catalyst.

Evidence & confidence

The article only provides the day’s move and does not explain why ENLT traded higher.

$TEVABullishLow confidence
Context

Teva Pharmaceutical Industries rose 2.50% while chip companies dragged the Tech Index lower.

Expected impact

Near-term relative strength possible, but direction depends on whether the chip selloff broadens.

Evidence & confidence

No company-specific news is provided, only the intraday price change and index context.

Market effects

Chip companies were the main drag on the Tech Index, implying correlated downside risk across TASE-listed semis/tech exposures.

Israel equities were broadly flat overall, but tech/chips showed clear internal dispersion.

Limited direct global linkage in the text; mainly a local TASE sector tape read-through.

Counterpoint

The broader indices were nearly flat, so the chip selloff may be a short-lived rotation rather than a fundamental repricing.

Key entities

  • Tel Aviv 35 Index

    Up 0.04% to 4,176.34 points, indicating the overall market was flat.

  • Tech Index

    Down 1.6%, led by chip companies, signaling sector-specific weakness.

  • Tower Semiconductor

    Down 8.71% as the biggest fall on the Tel Aviv 35 Index.

Related articles

$TSEMHighAI 8/10

Tower Semiconductor’s $1.2B Profit Roadmap Faces Its Biggest Test Yet in Q3 Earnings

Tower Semiconductor (TSEM) reports Q3 earnings on November 2, with shares down 21.25% in the past month. Q2 saw record revenue of $460.08M and adjusted EPS of $0.88, prompting raised 2028 targets to $3.6B revenue and $1.2B net profit. Analysts expect Q3 EPS of $1.0663 and revenue of $522.06M, with silicon photonics (SiPho) expansion and capacity timing as key focus areas.

$TEVAMed

25%–40% of patients with schizophrenia or bipolar I or II have acute agitation. Teva bought rights to a treatment under FDA review for home use.

Teva Pharmaceuticals acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The acquisition supports Teva's growth strategy and addresses an unmet patient need. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition. Teva aims to expand its neuroscience portfolio with this late-stage asset.

$TEVAMed

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals (TEVA) acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The deal, valued at up to $67.5M, expands Teva's neuroscience pipeline and aligns with its growth strategy. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition.

$TSEMHigh

TSEM Stock Pops As Semtech AI SiGe Deal Locks In Capacity

Tower Semiconductor (TSEM) stock rose 8.81% after expanding a multi-year silicon germanium manufacturing agreement with Semtech. The deal secures dedicated capacity for Semtech across TSEM's global facilities, tying TSEM to AI data center growth. TSEM trades at 16.5x sales and 8.9x book value, with $1.57B revenue and $17.95B enterprise value. The stock corrected from $258 to $179 recently, with support near $170.

$TEVAMed

Once-Monthly Olanzapine for Schizophrenia, With Christoph Correll, MD

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia, was approved based on the SOLARIS trial. The trial showed significant symptom reduction compared to placebo. Dr. Christoph Correll, principal investigator, highlighted the benefits of long-acting injectables in reducing relapse and improving patient outcomes. Weltruza's subcutaneous administration aims to address patient reluctance and resource limitations of previous treatments.